Scientific Rationale for Waiving Clinical Efficacy Testing of Biosimilars

Overview of attention for article published in Drug Design, Development and Therapy, August 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#29 of 2,306)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

So far, Altmetric has seen 17 news stories from 17 outlets.

CHICAGO, Nov. 22, 2022 /PRNewswire/ -- To reduce the cost of development of the approval of biosimilars, the FDA is encouraging…

CHICAGO, Nov. 22, 2022 /PRNewswire/ -- To reduce the cost of development of the approval of biosimilars, the FDA is encouraging…

CHICAGO, Nov. 22, 2022 /PRNewswire/ -- To reduce the cost of development of the approval of biosimilars, the FDA is encouraging…

CHICAGO, Nov. 22, 2022 /PRNewswire/ -- To reduce the cost of development of the approval of biosimilars, the FDA is encouraging…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 13 additional news stories.